A trial-off Ig therapy is planned or reason is provided as to why a trial is not being planned. The dosing approach is the same for both Dose IgM paraproteinaemic neuropathy with significant indications. progressive disability where other therapies have Induction - 2 g/kg in 2 to 5 divided doses. failed or are contraindicated Induction dose is unchanged. Induction - 2 g/kg in 2 to 5 divided doses. The minimum dose was set to 0.01 to Maintenance - 0.4–1 g/kg, 2–6 weekly. accommodate doses less than 0.4mg/Kg which Maintenance: 0.4–1 g/kg, 2 to 6 weekly. The amount per dose should be titrated to the could be efficacious. (A) individual’s response. The amount per dose should be titrated to the individual’s response. A maximum dose of 2 g/kg may be given in any four-week period. This might be The maximum dose interval was set to 8 Aim for minimum dose to maintain optimal by divided doses more frequently than fortnightly. weekly. A divided dose is supported for functional status. maintenance to allow the splitting of a 4 week Aim for minimum dose to maintain optimal total dose to be given up to weekly. (B) Refer to the current product information sheet functional status. for further information. Refer to the current product information sheet for The aim should be to use the lowest dose further information. possible that achieves the appropriate clinical outcome for each patient. Relapse of patients with IgM paraproteinaemic neuropathy within six months commencement of trial-off Ig therapy. Once a patient has relapsed when trialled off Ig treatment, a second-line immunomodulatory agent should be strongly considered as additional therapy. Induction: 2 g/kg in 2 to 5 divided doses. Maintenance: 0.4–1 g/kg, 2 to 6 weekly. The amount per dose should be titrated to the individual’s response. A maximum dose of 2 g/kg
A trial-off Ig therapy is planned or reason is provided as to why a trial is not being planned. Dose Induction - 2 g/kg in 2 to 5 divided doses. Maintenance - 0.4–1 g/kg, 2–6 weekly. The amount per dose should be titrated to the individual’s response. Aim for minimum dose to maintain optimal functional status. Refer to the current product information sheet for further information. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. IgM paraproteinaemic neuropathy with significant progressive disability where other therapies have failed or are contraindicated Induction - 2 g/kg in 2 to 5 divided doses. Maintenance: 0.4–1 g/kg, 2 to 6 weekly. The amount per dose should be titrated to the individual’s response. A maximum dose of 2 g/kg may be given in any four-week period. This might be by divided doses more frequently than fortnightly. Aim for minimum dose to maintain optimal functional status. Refer to the current product information sheet for further information. Relapse of patients with IgM paraproteinaemic neuropathy within six months commencement of trial-off Ig therapy. Once a patient has relapsed when trialled off Ig treatment, a second-line immunomodulatory agent should be strongly considered as additional therapy. Induction: 2 g/kg in 2 to 5 divided doses. Maintenance: 0.4–1 g/kg, 2 to 6 weekly. The amount per dose should be titrated to the individual’s response. A maximum dose of 2 g/kg The dosing approach is the same for both indications. Induction dose is unchanged. The minimum dose was set to 0.01 to accommodate doses less than 0.4mg/Kg which could be efficacious. (A) The maximum dose interval was set to 8 weekly. A divided dose is supported for maintenance to allow the splitting of a 4 week total dose to be given up to weekly. (B)